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Background
4Catch-up schedule: current and proposed
Current adolescent and adult catch-up schedule series for those with 
incomplete or unknown vaccine history 
Proposed policy option under consideration
5Catch-up schedule: current and proposed
 Limited data exist on the safety of the current vs. the proposed catch-up 
schedule for adolescents and adults 
 An approach to address this issue is to look at published and unpublished 
data on the safety of:
• Immunization regimens similar to proposed schedule
• Administering closely spaced (≤12 months) Tdap doses
6Objectives
 Review published literature on studies that have assessed the safety 
of closely spaced Tdap: 
• Compared to closely spaced Td doses
• Non-comparative, descriptive
 Review unpublished safety data on closely spaced Tdap from CDC’s 
vaccine safety monitoring systems:
• Vaccine Adverse Event Reporting System (VAERS)
• Vaccine Safety Datalink (VSD)
Published studies
8Study of Tdap vs. Td1
 Study design: double-blind, randomized, controlled clinical trial
 Study population: 460 adults ≥ 40 years from 3 European countries with 
no Td vaccine for 20 years or unknown vaccination history
 Study arms: received the following in a 0-1-6 month schedule:
• 3 doses of Tdap
• 1 dose of Tdap-IPV followed by 2 doses of Td, or 
• 3 doses of Td vaccine (control) 
 Outcomes: immunogenicity and reactogenicity
 Results: No statistically significant differences in local or general symptoms 
between groups were observed
1 Theeten H, et al. Current Medical Research and Opinion. 2007;23:11,2729-2739
9Study of maternal Tdap reactogenicity1
 Study design: cohort study
 Study population: 374 pregnant women; 225 nonpregnant women
 Study sub-population of interest: 8 pregnant women who had more than 
one Tdap within the past 12 months 
 Comparison groups: none
 Outcomes: injection site and systemic reactions
 Results: no severe local or systemic reactions 
 Conclusion: no adverse event of concern but small number of subjects
1 Fortner K, et al. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and 
non-pregnant women. Vaccine. 2018 Oct  8;36(42):6354-6360
Vaccine Adverse Event Reporting System 
(VAERS)
Unpublished analysis
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Vaccine Adverse Event Reporting System (VAERS)
Strengths
 National data 
 Rapidly detects safety signals 
 Can detect rare adverse events
 Data available to public
 Accepts reports from anyone
Limitations
 Reporting bias 
 Inconsistent data quality and 
completeness
 Lack of unvaccinated comparison group
 Generally cannot assess causality
VAERS accepts all reports from all reporters without making judgments on causality, 
irrespective of clinical seriousness
As a hypothesis generating system, VAERS identifies potential vaccine safety concerns 
that can be studied in more robust data systems• VAERS accepts all reports from all reporters without making judgments on 
causality, irrespective of clinical seriousness
• As a hypothesis generating system, VAERS identifies potential vaccine safety 
concerns that can be studied in more robust data systems
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Closely spaced Tdap reports in VAERS - Methods 
(unpublished data)
 Search VAERS database for U.S. reports of all persons who received 
more than one dose of Tdap
• Jan 1, 1990 – June 30th, 2019
 Review of VAERS reports and any medical records to assess for the 
length of interval between doses and the adverse event (AE), if any
 Reports where interval of two Tdap doses ≤12 months included in 
final analysis
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Closely spaced Tdap reports in VAERS – Findings 
(unpublished data)
 Among 34,804 reports of Tdap submitted to VAERS during the search 
period, 342 involved multiple doses of Tdap 
 In 88 reports interval of two Tdap doses ≤12 months  
• 67 (76.1%) did not describe an AE (vaccination errors)
• 21 (23.9%) described an AE 
 The most common AEs were injection site reactions in 8 reports
Vaccine Safety Datalink (VSD)
Unpublished analysis
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Retrospective Cohort Study assessing repeated doses 
of Tdap vs. Td – unpublished analysis
 Data source: unpublished data from VSD retrospective cohort study 
evaluating repeated Tdap doses
• Supplementary analysis on existing dataset1
 Study sub-population of interest (unpublished data): 13,599 non-pregnant 
adolescents and adults 11-64 years who received Tdap or Td within 12 
months of prior Tdap 
 Comparison groups:
• 11,687 Tdap vs. 1,912 Td vaccines given within 12 months of prior Tdap 
 Outcomes:  pre-specified local reactions and neurologic adverse events2
 Results: Repeated Tdap was not associated with an increase in any adverse 
event compared to Td within 12 months of prior Tdap 
1 Jackson M, et al. Pharmacoepidemiol Drug Saf. 2018;27:921-925
2 Cellulitis, Limb swelling, Pain in limb, Encephalopathy, encephalitis and/or meningitis, Paralytic syndromes, Seizure, Cranial nerve disorders, Guillain-Barre Syndrome
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Maternal Tdap safety in the VSD – unpublished analysis 
 Data source: unpublished data from VSD retrospective cohort study 
evaluating maternal Tdap safety
 Study sub-population of interest (unpublished data): 187 women with 
multiple Tdap vaccines during the same pregnancy (excluded from larger 
published study1)
 Comparison group: None
 Outcomes:  acute adverse events (fever, allergy, and local reactions) and 
adverse birth outcomes (small for gestational age, preterm delivery, and 
low birth weight)
1 Sukumaran L et al. JAMA. 314(15):1581-1587
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Maternal Tdap safety in the VSD – unpublished analysis (cont.)
 Only 1/187 with acute event following multiple Tdap vaccines in 
same pregnancy
• ICD-9 code of limb pain and limb swelling 7 days after vaccination 
• Occurred on the day of delivery
• Affected limb(s) unspecified 
• Baby born at 39 weeks
 Birth outcome rates were similar to pregnant women exposed to a 
single Tdap dose during the same pregnancy1
1 Sukumaran L et al. JAMA. 2015;314(15):1581-7
Summary and Conclusions
19
Summary - Published Studies
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Summary - unpublished data
VAERS:
 Most reports (76%) of excess doses of Tdap in VAERS did not describe 
an AE
 Among reports with AEs (n=21), local reactions were most commonly 
reported (n=8)
VSD:
 Among subjects who received a Tdap dose ≤12 months compared to 
Td, no increased rates of AEs were observed
 Among 187 women in the VSD who received multiple Tdap doses in 
the same pregnancy, one presented with limb pain and limb swelling 7 
days after vaccination (unclear if related) 
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Conclusions
 Published data on closely spaced Tdap doses shows no increase in AEs 
when Tdap or Td was administered as a second or third dose
• Regimens similar to the current and proposed catch-up schedule did 
not show differences in reactogenicity
 Unpublished data of closely spaced Tdap doses shows no unusual or 
increased reporting of any AE
 While data on multiple Tdap doses is limited, our review of published and 
unpublished safety data is reassuring 
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